000128368 001__ 128368
000128368 005__ 20240228135054.0
000128368 0247_ $$2doi$$a10.1016/j.ccell.2014.11.005
000128368 0247_ $$2pmid$$apmid:25490450
000128368 0247_ $$2ISSN$$a1535-6108
000128368 0247_ $$2ISSN$$a1878-3686
000128368 0247_ $$2altmetric$$aaltmetric:2970506
000128368 037__ $$aDKFZ-2017-04385
000128368 041__ $$aeng
000128368 082__ $$a610
000128368 1001_ $$0P:(DE-He78)68be8daf09675910338d6eca0149b182$$aSrivastava, Kshitij$$b0$$eFirst author$$udkfz
000128368 245__ $$aPostsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth.
000128368 260__ $$aCambridge, Mass.$$bCell Press$$c2014
000128368 3367_ $$2DRIVER$$aarticle
000128368 3367_ $$2DataCite$$aOutput Types/Journal article
000128368 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521200322_1730
000128368 3367_ $$2BibTeX$$aARTICLE
000128368 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128368 3367_ $$00$$2EndNote$$aJournal Article
000128368 520__ $$aAntiangiogenic tumor therapy has failed in the adjuvant setting. Here we show that inhibition of the Tie2 ligand angiopoietin-2 (Ang2) effectively blocks metastatic growth in preclinical mouse models of postsurgical adjuvant therapy. Ang2 antibody treatment combines well with low-dose metronomic chemotherapy (LDMC) in settings in which maximum-dose chemotherapy does not prove effective. Mechanistically, Ang2 blockade could be linked to quenching the inflammatory and angiogenic response of endothelial cells (ECs) in the metastatic niche. Reduced EC adhesion molecule and chemokine expression inhibits the recruitment of tumor-promoting CCR2(+)Tie2(-) metastasis-associated macrophages. Moreover, LDMC contributes to therapeutic efficacy by inhibiting the recruitment of protumorigenic bone marrow-derived myeloid cells. Collectively, these data provide a rationale for mechanism-guided adjuvant tumor therapies.
000128368 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000128368 588__ $$aDataset connected to CrossRef, PubMed,
000128368 650_7 $$2NLM Chemicals$$aAdjuvants, Pharmaceutic
000128368 650_7 $$2NLM Chemicals$$aAngiogenesis Inhibitors
000128368 650_7 $$0P88XT4IS4D$$2NLM Chemicals$$aPaclitaxel
000128368 7001_ $$0P:(DE-HGF)0$$aHu, Junhao$$b1
000128368 7001_ $$0P:(DE-He78)9f5445b47d46f5f026560c307119a7da$$aKorn, Claudia$$b2$$udkfz
000128368 7001_ $$0P:(DE-HGF)0$$aSavant, Soniya$$b3
000128368 7001_ $$0P:(DE-HGF)0$$aTeichert, Martin$$b4
000128368 7001_ $$0P:(DE-He78)8a953c029cb5b686e638301dc826fe59$$aKapel, Stephanie$$b5$$udkfz
000128368 7001_ $$0P:(DE-He78)f12dec7b80065347181cf69f8233b40d$$aJugold, Manfred$$b6$$udkfz
000128368 7001_ $$0P:(DE-He78)9be9200416a88a73cc9c25339b19b58f$$aBesemfelder, Eva$$b7$$udkfz
000128368 7001_ $$aThomas, Markus$$b8
000128368 7001_ $$aPasparakis, Manolis$$b9
000128368 7001_ $$0P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aAugustin, Hellmut$$b10$$eLast author$$udkfz
000128368 773__ $$0PERI:(DE-600)2074034-7$$a10.1016/j.ccell.2014.11.005$$gVol. 26, no. 6, p. 880 - 895$$n6$$p880 - 895$$tCancer cell$$v26$$x1535-6108$$y2014
000128368 909CO $$ooai:inrepo02.dkfz.de:128368$$pVDB
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)68be8daf09675910338d6eca0149b182$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9f5445b47d46f5f026560c307119a7da$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8a953c029cb5b686e638301dc826fe59$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f12dec7b80065347181cf69f8233b40d$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9be9200416a88a73cc9c25339b19b58f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000128368 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2e92d0ae281932fc7347d819fec36b0b$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000128368 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000128368 9141_ $$y2014
000128368 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CELL : 2015
000128368 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128368 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128368 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128368 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128368 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128368 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128368 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128368 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128368 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128368 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128368 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128368 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128368 915__ $$0StatID:(DE-HGF)9920$$2StatID$$aIF >= 20$$bCANCER CELL : 2015
000128368 9201_ $$0I:(DE-He78)A190-20160331$$kA190$$lVaskuläre Onkologie und Metastasierung$$x0
000128368 980__ $$ajournal
000128368 980__ $$aVDB
000128368 980__ $$aI:(DE-He78)A190-20160331
000128368 980__ $$aUNRESTRICTED